Benchmark: FDA Reclassification of Hepatitis B Virus (HBV) Assay Devices: Compliance and Implementation Training

Take this benchmark to assess how much you would benefit from taking the course on Compliance and Implementation of the FDA Final Rule on Reclassification of Hepatitis B Virus (HBV) Assay Devices. In a few minutes, you’ll see how well you understand the rule’s intent, who it impacts, and what it asks you to do.

What you’ll get:
– A quick read on your grasp of five areas: policy intent, operational impact, equity/access implications, program philosophy, and practical readiness
– Insight into trade-offs you’ll need to manage (e.g., speed to market vs. safety guardrails; flexibility vs. compliance)
– Clear signals on where the course can save you time and reduce risk (special controls, 510(k) strategy, labeling, PCCPs, and postmarket obligations)

Who should take this benchmark:
– Anyone touching HBV assays—manufacturing, regulatory, quality, clinical/lab operations, product, and compliance teams

How to use your results:
– Many correct responses: you likely need targeted refreshers
– Mixed results: the full course will help you translate requirements into action
– Mostly incorrect: start with policy intent and special controls, then move to 510(k), labeling, and change management

The goal: make it obvious whether this training will accelerate your submissions, strengthen compliance, and improve patient access—before you invest more time.